European Commission authorizes new treatment for metastatic pancreatic cancer

The European Commission has authorized the marketing of Daraxonrasib for treating adults with metastatic pancreatic cancer who have already undergone at least one previous line of treatment. The drug underwent an accelerated regulatory process, and a joint clinical evaluation by EU member states is expected to be available in December 2026 to facilitate access.
